DelveInsight's Influenza Vaccine Market Insights report provides the current and forecast market analysis, individual leading ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...

Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted)NEW YORK, ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

On Tuesday, Merck ... average growth profile. A BofA analyst notes that Merck has one of the strongest late-stage drug pipelines among its peers and remains a top-tier R&D company.

Co., Inc. (NYSE:MRK), recently acquired 15,000 shares of the company's common stock. The transaction, which took place on ...

Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

Mr. Iwicki succeeds Dr. Milton H. Werner, founder of Inhibikase. Mr. Munshi succeeds Mr. Bellini as Chairman of Board of ...

Organon & Co. (NYSE:OGN), a global healthcare company spun off from Merck (NSE:PROR) in 2021, has established itself as a leader in women's health while expanding its presence in biosimilars and ...

Mr. Iwicki Brings Track Record of Operational Excellence and Significant Expertise in PAH and Cardiovascular Diseases -- -- Amit Munshi Appointed Chair of the Board of Directors -- BOSTON, Feb.

The transaction, expected to close in the first half of this year, will cost Novartis $925 million upfront with potential ...